Global private equity firm Bridgepoint bought a majority stake in HTL SAS, a French maker of hyaluronic acid and its byproducts, for an undisclosed sum.

Investment firm Naxicap Partners, which specializes in direct and fund of fund investments, sold the stake but will reinvest in HTL through a substantial minority interest.

Bridgepoint focuses on lower-middle-market buyouts and growth investments in small markets.